A randomised Phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
You are leaving Smmttx.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible
for
its contents.
Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.
To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.
A randomised Phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections